在胰岛素初始T2D患者中，固定剂量每周efsitora在52周时降低HbA1c的效果不低于每日甘精。

IF 15.2 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of Internal Medicine Pub Date : 2025-10-07 DOI:10.7326/ANNALS-25-03845-JC

Michael Tanner

引用次数: 0

摘要

临床影响评分：GIM/FP/GP:[公式：见文]内分泌学：[公式：见文]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

In insulin-naive T2D, fixed-dose weekly efsitora was noninferior to daily glargine for reducing HbA_1c at 52 wk.

Clinical impact ratings: GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Internal Medicine 医学-医学：内科

CiteScore

23.90

自引率

1.80%

发文量

1136

审稿时长

3-8 weeks

期刊介绍： Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.